The value of MMP-7 combined with serological markers in diagnosing liver fibrosis in children with biliary atresia Authors: Bingliang Li, Yingyu Jia, Yanfu Wang, Zhibo Zhang, Hongxia Ren Published: 2025 ABSTRACT AbstractObjectiveTo explore the diagnostic value of Matrix Metallopeptidase 7 (MMP-7) alongside serological markers in identifying liver fibrosis in children with biliary atresia (BA).MethodsA retrospective study was conducted to analyze the general information, liver fibrosis stage, and laboratory results, including MMP-7, of children with BA who underwent Kasai portoenterostomy between 2022 and 2024 at two Chinese hospitals. The aspartate aminotransferase to platelet ratio index (APRI), Fibrosis 4 Score (FIB-4), and infant biliary atresia liver fibrosis (iBALF) score were calculated according to the formula.ResultsSignificant differences in APRI, FIB-4, iBALF score, and MMP-7 were observed across fibrosis stages.When differentiating different stages of liver fibrosis, FIB-4 demonstrated the highest AUC values (0.807 and 0.815) for identifying liver fibrosis stages ≥ F2 and ≥ F3, and the optimal cut-off values were 0.073 and 0.105. For evaluating stage F4, MMP-7 showed the highest AUC value of 0.793, with an optimal cut-off of 68.94. Combining MMP-7 with other markers improved diagnostic accuracy, particularly MMP-7 + iBALF score for cirrhosis (F4: AUC = 0.844).ConclusionSerological markers like FIB-4, iBALF score, and MMP-7 can reflect various levels of liver fibrosis. Among these, the combination of MMP-7 and iBALF score is the most effective in differentiating liver cirrhosis.Keywords: MMP-7, Serological marker, Liver fibrosis, Biliary atresia, iBALF score Introduction Biliary atresia (BA) is a neonatal liver disease characterized by progressive fibrous occlusion of the bile ducts inside and outside the liver, the etiology of which is not well understood, often leads to cholestasis and secondary cirrhosis, and is the leading cause of liver transplantation in children [1, 2]. Liver fibrosis is not only a key prognostic indicator for the efficacy of Kasai portoenterostomy (KPE), but also an important basis for guiding the timing of liver transplantation intervention [3, 4]. Although histopathological examination is still the gold standard for staging fibrosis, the inherent risks of trauma, sampling error, and other limitations have prompted the clinical need to establish a reliable noninvasive assessment system [5, 6], so the development of efficient and safe noninvasive diagnostic tools has become an urgent need. In recent years, non-invasive evaluation methods based on serum biomarkers and imaging techniques have gradually become a research hotspot. In terms of serological assessment, aspartate aminotransferase to platelet ratio index (APRI) is currently a commonly used indicator in the evaluation of liver fibrosis in children with BA [7], and the fibrosis-4 score (FIB-4) has shown good diagnostic efficacy in predicting progressive fibrosis in some studies [8, 9]. Of particular concern is the infant biliary atresia liver fibrosis (iBALF) score, developed for ≤ 1-year-old children with BA, which showed a significant correlation with the stage of liver fibrosis [10]. Among imaging evaluation techniques, ultrasound elastography (including two-dimensional shear wave elastography and transient elastography) can assess the stage of liver fibrosis by quantifying liver stiffness value (LSM), but it is easily interfered by factors such as operator dependence, hepatic steatosis, and special physiological status of infants and young children, and has high requirements for equipment and technology, which restricts its popularization and application in primary medical institutions [11–14]. In recent years, matrix metalloproteinase-7 (MMP-7) has been a key regulator of hepatic stellate cell activation and extracellular matrix remodeling, and its serum levels are significantly positively correlated with the degree of fibrosis in children with BA [15, 16]. However, there is still a lack of research on the diagnostic efficacy of MMP-7 in combination with other serum markers, and there is a lack of evidence for the optimization of cut-off values based on different fibrosis stages. The purpose of this study was to systematically evaluate the value of MMP-7 combined with different serological markers in the hierarchical diagnosis of liver fibrosis in children with BA, in order to provide a low-cost, easy-to-operate non-invasive evaluation scheme for primary medical institutions, and to provide a theoretical basis for a multimodal diagnostic model integrating serology and imaging. Materials and methods Patients This study is a retrospective study, between July 2022 and July 2024, a total of 68 children were initially diagnosed with BA and considered for liver biopsy. After applying the inclusion and exclusion criteria, 14 patients were excluded.Ultimately, 54 children (25 boys and 29 girls) were included in this study.The inclusion criteria were: (1) children with a confirmed BA diagnosis through intraoperative exploration and/or cholangiography; (2) liver tissue biopsy taken during surgery; (3) complete data on routine laboratory test indicators, and MMP-7 levels. The exclusion criteria included: (1) 2 cases due to perioperative deaths(complicated with other cardiac, cerebral or metabolic diseases); (2) 3 cases due to lack of liver pathological examination; (3) 9 cases due to incomplete clinical or laboratory data. Informed consent was obtained from the children’s families, and the study was approved by the Ethics Committee of Shanxi Children’s Hospital (IRB-WZ-2024-031),and the requirement for written consent was waived. Clinical data and liver tissue sample collection Data were retrospectively extracted from medical records, including preoperative laboratory results (obtained within 3 days before surgery) and histopathological findings from liver biopsies performed during KPE.Clinical data were collected: (1) Basic information: gender, age of surgery. (2) Results of liver fibrosis staging based on pathology. (3) Laboratory results within 3 days before surgery, including alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyl transpeptidase (GGT), serum albumin (ALB), total bilirubin (TBIL), direct bilirubin (DBIL), total bile acid (TBA), alkaline phosphatase (ALP), platelet (PLT), MMP-7. Serum MMP-7 levels were measured using the magnetic particle chemiluminescence method (kit: produced by Tianjin Aoce Company, Tianjin, China), based on the principle of double antibody sandwich method, using biotinylated MMP-7 monoclonal antibody (capture reagent: produced by Tianjin Aoce Company, Tianjin, China), pyridine ester-labeled polyclonal antibody (luminescent reagent: produced by Tianjin Aoce Company, Tianjin, China) and streptavidin magnetic particles (solid phase carrier). The detection instrument was SMART 500 S automatic chemiluminescence immunoassay analyzer, and the result was judged to be positive with an S/CO ratio of ≥ 1.0.Liver tissue samples were collected during surgery from the leading edge of the right lobe, fixed in 10% formaldehyde, embedded in paraffin, and then sectioned by pathologists. These sections were stained with hematoxylin-eosin and Masson, and the level of liver fibrosis was assessed using a light microscope.Liver tissue samples were independently evaluated by two experienced pathologists for fibrosis staging using the METAVIR system. The inter-observer agreement was tested by Kappa coefficient test (P < 0.001), and the final staging of the divergent cases was determined after review by a third senior pathologist. Serum diagnostic markers calculation The outcomes of each serological markers were determined using the specified formula: aspartate aminotransferase to platelet ratio index (APRI), Fibrosis 4 Score (FIB-4) and infant biliary atresia liver fibrosis (iBALF) score. In this retrospective study, these markers were computed using preoperative laboratory test results obtained within 3 days before surgery and were compared with the intraoperative liver biopsy findings, which served as the gold standard for fibrosis staging.For the purpose of calculating the APRI, the AST upper limit of normal (ULN) was established at 40 U/L, in accordance with our laboratory standards. [7, 8, 10] Fibrosis staging Liver fibrosis was staged according to the METAVIR system [17]: F0 (no fibrosis), F1 (mild fibrosis), F2 (moderate fibrosis), F3 (severe fibrosis), and F4 (cirrhosis). Following clinicopathological criteria, stages ≥ F2, ≥F3, and F4 were defined as significant fibrosis, advanced fibrosis, and cirrhosis, respectively. Statistical analysis Statistical analysis was conducted using SPSS 26.0. The measurement data were described by (‾x ± s)or M (Q1, Q3) according to whether they obeyed the normal distribution. The counting data were described by frequency and composition ratio. The univariate ANOVA test was used for comparison between groups. The Spearman rank correlation coefficient was used to test the correlation between different data, and the multivariate logistic regression analysis was performed after adjusting for potential confounding factors.The receiver operating characteristic (ROC) curve was used to analyze the diagnostic performance of each serological marker on the stage of liver fibrosis, and the area under the curve (AUC) was calculated, with the largest Youden index as the best cut-off value. The Delong test was used to compare the diagnostic value of different ROC curves. A p-value < 0.05 was considered statistically significant. Results Basic datas comparison Among the 54 children included, F1 (n = 8), F2 (n = 17), F3 (n = 14), and F4 (n = 15) were included. Significant differences were observed in the age of surgery, AST, GGT, APRI, FIB-4, iBALF score, and MMP-7 between the four groups (Table 1), no significant differences were found in ALT, ALB, TBIL, DBIL, TBA, and ALP. Table 1Clinical serologic features of different stages of liver fibrosisParametersF1(n = 8)F2(n = 17)F3(n = 14)F4(n = 15)Z/X2 P SEX(n(%))6.0340.11 Male2(25%)9(52.9%)4(28.6%)10(66.7%) Age at Surgery(d) 42.0 ± 19.8752.47 ± 22.2363.29 ± 17.9474.2 ± 24.774.783 0.005 ALT(U/L)136.2(88.7,212.8)94(55.9,170.5)133(85.9,312.5)154.5(125.8,292.3)2.1070.111 AST(U/L) 182.7(90.6,297.2)158.0(96.2,188.4)195.5(159.3,409.5)231.2(140.8,363.5)2.843 0.047 GGT(U/L) 390(129,615)461(336,641)493(193,938)939(666,1295)3.548 0.021 ALB(g/L)36.8(33.8,41.7)37.4(34.6,39.3)37.1(32.0,38.8)38.1(32.2,42.1)0.5820.630TBIL(µmol/L)167.6(103.4,310.3)153.7(133.1,218.4)171.7(135.1,201.9)195(162.2,220.9)0.3380.798DBIL(µmol/L)143.9(78.0,247.9)103.2(91.0,136.9)124.9(94.6,173.3)134.8(96.9,160.6)1.2150.314TBA(µmol/L)113.8(87.9,147.3)108.9(85.1,138.3)131.2(100.9,158.1)125.8(110.2,153.6)0.6040.615ALP(U/L)451.5(344.5,746.5)504(393.5,669.5)459(375,764)482(410,584)0.2070.891 APRI 0.938(0.452,1.351)0.924(0.618,1.122)1.085(0.895,2.834)1.668(1.078,2.919)3.548 0.021 FIB-4 0.052(0.02,0.088)0.076(0.039,0.099)0.121(0.078,0.173)0.169(0.096,0.21)5.358 0.003 iBALF score 6.307 ± 1.1377.017 ± 0.7787.329 ± 0.7877.916 ± 0.8386.728 0.001 MMP-7(ng/ml) 33.7(21.2,58.4)43.4(26.5,82.0)47.0(29.1,76.8)116.1(74.8,171.2)7.481 <0.001 The P values in the table represent the overall comparison across the four stages of liver fibrosisThe data in the table are expressed as n (%), ‾x ± s or M (Q1, Q3)The bold items in the table are P < 0.05 Clinical serologic features of different stages of liver fibrosis The P values in the table represent the overall comparison across the four stages of liver fibrosis The data in the table are expressed as n (%), ‾x ± s or M (Q1, Q3) The bold items in the table are P < 0.05 Correlation analysis between surgical age, liver fibrosis stage, and MMP-7 Spearman rank correlation analysis showed that there was a significant positive correlation between surgical age and liver fibrosis stage (ρ = 0.446, P < 0.001), and serum MMP-7 level was also significantly positively correlated with surgical age (ρ = 0.408, P = 0.002) and liver fibrosis stage (ρ = 0.409, P = 0.002). After the multivariate linear regression model was used to correct for confounding factors, MMP-7 remained independently and positively correlated with surgical age (β = 0.338, P = 0.013). Comparison of diagnostic efficacy in distinguishing F1 ~ F4 stages among various serological markers Taking the pathological results of liver biopsy of 54 children as the “gold standard”, six statistically significant serological markers in Table 1 were included in the study, and their AUC, optimal cut-off value, sensitivity and specificity were calculated. Among them, FIB-4 demonstrated the highest AUC values (0.807 and 0.815) for diagnosing significant liver fibrosis (≥ F2) and advanced liver fibrosis (≥ F3), with optimal cut-off values of 0.073 (sensitivity 76.1%, specificity 75%) and 0.105 (sensitivity 65.5%, specificity 88%), respectively. MMP-7 had the highest AUC value of 0.793, with a cut-off value of 68.94, sensitivity of 86.7%, and specificity of 71.8% for diagnosing liver cirrhosis (= F4). The ROC curve results for the serological markers at various stages of liver fibrosis are presented in Table 2; Fig. 1, of the six serum markers included in the analysis, only FIB-4 and MMP-7 showed statistically significant diagnostic value for the stage of liver fibrosis (P < 0.05 on DeLong test). Table 2Comparison of the efficacy of individual serological marker for diagnosing the stage of liver fibrosisSerological markers≥F2≥ F3= F4AST AUC0.5310.6990.61 95%CI0.317–0.7450.561–0.8380.439–0.781 Sensitivity/Specificity0.196/10.655/0.680.533/0.769 Cut off354.05175.5218.7GGT AUC0.6470.6830.78 95%CI0.417–0.8760.535–0.8310.636–0.925 Sensitivity/Specificity0.478/0.8750.621/0.840.667/0.821 Cut off648.5683730.5APRI AUC0.6550.7670.711 95%CI0.476–0.8340.642–0.8920.547–0.875 Sensitivity/Specificity0.326/10.69/0.760.733/0.718 Cut off1.6331.0731.214FIB-4 AUC0.8070.8150.767 95%CI0.661–0.9530.703–0.9270.624–0.909 Sensitivity/Specificity0.761/0.750.655/0.880.867/0.641 Cut off0.0730.1050.095iBALF score AUC0.7660.720.768 95%CI0.572–0.9610.585–0.8550.624–0.911 Sensitivity/Specificity0.978/0.50.966/0.40.733/0.718 Cut off5.7386.4297.503MMP-7 AUC0.7010.6650.793 95%CI0.536–0.8660.519–0.8110.628–0.958 Sensitivity/Specificity0.543/0.8750.655/0.720.867/0.718 Cut off60.6160.6168.94 Comparison of the efficacy of individual serological marker for diagnosing the stage of liver fibrosis The diagnostic efficacy of each indicator for the staging of liver fibrosis A ≥ F2 B ≥ F3 C = F4 MMP-7 combined with various serological markers to evaluate the efficacy of F1-F4 stages MMP-7 was analyzed in conjunction with AST, GGT, APRI, FIB-4, and iBALF score, and the AUC, sensitivity, and specificity for MMP-7 were determined. The combination of MMP-7 and FIB-4 yielded the highest AUC values (0.823 for ≥ F2 and 0.801 for ≥ F3), while the highest AUC for diagnosing F4 was 0.844 when MMP-7 was combined with the iBALF score. This indicates that the combination of MMP-7 and FIB-4 is particularly effective in identifying significant liver fibrosis (≥ F2), and the pairing of MMP-7 with the iBALF score is most valuable for distinguishing liver cirrhosis (F4). The ROC curve results illustrating the combined diagnostic performance of these serological markers at various stages of liver fibrosis are presented in Table 3; Fig. 2, with P < 0.05 on DeLong test. Table 3Comparison of the efficacy of MMP-7 combined with various serological markers for diagnosing the stage of liver fibrosisSerological markersF1 and F2 ~ F4F1 ~ F2 and F3 ~ F4F1 ~ F3 and F4MMP-7 + AST AUC0.7040.7320.805 95%CI0.559–0.8490.596–0.8690.642–0.968 Sensitivity/Specificity0.5/10.69/0.760.867/0.744MMP-7 + GGT AUC0.6930.6650.795 95%CI0.531–0.8550.519–0.8110.63–0.96 Sensitivity/Specificity0.543/0.8750.655/0.720.867/0.718MMP-7 + APRI AUC0.7470.7930.8 95%CI0.614–0.880.67–0.9160.641–0.959 Sensitivity/Specificity0.63/10.793/0.80.867/0.769MMP-7 + FIB-4 AUC 0.823 0.801 0.779 95%CI 0.704–0.943 0.684–0.919 0.625–0.934 Sensitivity/Specificity 0.717/0.875 0.69/0.84 0.8/0.769MMP-7 + iBALF score AUC0.810.754 0.844 95%CI0.653–0.9670.627–0.882 0.7-0.988 Sensitivity/Specificity0.609/0.8750.483/0.96 0.733/0.897 The items in bold in the table indicate the largest AUC in each stage of liver fibrosis Comparison of the efficacy of MMP-7 combined with various serological markers for diagnosing the stage of liver fibrosis The items in bold in the table indicate the largest AUC in each stage of liver fibrosis The diagnostic efficacy of combined indicators for staging liver fibrosis. A≥F2 B≥F3 C= F4 Discussion BA is a neonatal hepatobiliary disease characterized by progressive fibrous atresia of the intrahepatic and extrahepatic bile ducts, and its etiological mechanism has not been fully elucidated [1]. Although KPE significantly improves native liver survival (NLS) in children with BA, progression to progressive liver fibrosis is difficult to avoid in more than 60% of children [2]. Notably, although the degree of liver fibrosis is not a suitable predictor of NLS [18], its association with the progression of portal hypertension and the need for liver transplantation has been supported by several studies [2, 19]. Therefore, accurate assessment of liver fibrosis stage is of great clinical significance for optimizing the timing of KPE, making liver transplantation decisions, and monitoring portal hypertension-related complications. The core objective of our study is not to directly predict NLS, but to provide a clinical stratification tool to optimize perioperative management and complication monitoring. Although noninvasive diagnostic techniques based on serum biomarkers have been widely used in the field of liver fibrosis assessment [20], there is significant heterogeneity in the diagnostic efficacy of different indicators for fibrosis staging. In recent years, MMP-7 has become the focus of research due to its core regulatory role in hepatic stellate cell activation and extracellular matrix (ECM) remodeling. Beyond its classical role in directly mediating hepatic stellate cell activation and collagen deposition, MMP-7 contributes to fibrogenesis through additional pathways. Firstly, as a key mediator of epithelial-mesenchymal transition (EMT), MMP-7 facilitates the degradation of E-cadherin, promoting the transdifferentiation of biliary epithelial cells into myofibroblasts and thereby directly expanding the pool of fibrogenic effector cells [21]. Furthermore, MMP-7 activates latent transforming growth factor-β (TGF-β), amplifying its downstream signaling that drives hepatic stellate cell activation and collagen synthesis, and creating a cascade amplification effect in fibrotic signaling [22]. These multi-pathway synergistic mechanisms provide a pathophysiological basis for the strong correlation observed between MMP-7 levels and the degree of liver fibrosis in BA.Based on this, MMP-7 is considered to be a potential biomarker for dynamic monitoring of liver fibrosis in BA. Therefore, this study systematically compared MMP-7 with traditional indicators such as APRI, FIB-4 and iBALF score, aiming to use the degree of pathological fibrosis as the “gold standard” to detect the diagnostic value of each index on the stage of liver fibrosis, in order to find a relatively reliable non-invasive index for the diagnosis of liver fibrosis in BA. The results of this study showed that the six serological indexes had certain value in the evaluation of liver fibrosis in children with BA, and FIB-4 had the highest AUC value (0.807, 0.815) in the evaluation of significant liver fibrosis (≥ F2) and advanced liver fibrosis (≥ F3), and MMP-7 had the highest AUC value (0.793) in the evaluation of liver cirrhosis stage (= F4). This finding is similar to the findings of Jiang et al. [23], which confirmed that there was a strong positive correlation between preoperative serum MMP-7 levels and liver fibrosis stage (r = 0.71, P < 0.001), but no significant correlation between different fibrosis stages, which further validated the potential of MMP-7 as a fibrosis-specific marker. In contrast, the value of other traditional serological markers in the diagnosis of liver fibrosis staging remains controversial. In recent years, the diagnostic efficacy of APRI in the non-invasive evaluation of liver fibrosis has been widely discussed, but the conclusions show significant heterogeneity. Kim et al. [24] observed a significant correlation between APRI and the degree of liver fibrosis in 35 children with BA, and showed excellent performance in differentiating between METAVIR stages ≥ F3 (AUC = 0.92) and = F4 (AUC = 0.91). In the study of Mo et al. [25], APRI showed a significant difference in distinguishing between F2 ~ F4 and F3 ~ F4. This is similar to our findings: there is a correlation between APRI and stage of liver fibrosis, with APRI having a moderate diagnostic value of AUC = 0.682 at the time of diagnosing ≥ F2. In this study, FIB-4 performed more in diagnostic performance (≥ F2 AUC = 0.807, ≥ F3 AUC = 0.815), and its multivariate model integrating age, AST, ALT, and PLT effectively reduced the risk of bias caused by a single index, which was similar to the conclusion of Lyu et al. [9] (n = 214, AUC = 0.79). In addition, although traditional liver function measures such as serum TBA and TBIL can reflect the severity of hepatocellular injury and cholestasis [26–28], they have limited value in determining the degree of liver fibrosis, suggesting the limitations of these measures in dynamic monitoring of fibrosis. This further highlights the irreplaceability of new molecular markers represented by MMP-7 in the accurate assessment of liver fibrosis in BA. Although serology-based non-invasive diagnostic markers have attracted more and more attention in the evaluation of liver fibrosis in children with BA, systematic research on multiplex combined diagnostic models is still insufficient. Based on this, this study hopes to provide a basis for primary pediatricians to evaluate the degree of liver fibrosis in children with BA by comparing the combined diagnostic efficacy of multiple indicators for liver fibrosis. Chi et al. [29] tracked the dynamic changes in MMP-7 concentration and prognosis in children with BA from diagnosis to liver transplantation, and considered MMP-7 levels after KPE to be the earliest prognostic biomarker. They found that changes in serum MMP-7 concentrations at 6 weeks postoperatively were a significant predictor of NLS at 2 years postoperatively. In this study, MMP-7 was used in combination with serological indexes to improve the diagnostic performance of all stages of liver cirrhosis, especially when combined with iBALF score, the highest efficacy in distinguishing cirrhosis (= F4). Notably, FIB-4 showed robust efficacy in the diagnosis of significant liver fibrosis (≥ F2) and advanced fibrosis (≥ F3) (AUC = 0.807 and 0.815), and its diagnostic efficacy alone was close to that of the multiplex model. This result suggests that FIB-4 has important value as an independent indicator in clinical practice, especially in medical settings with limited resources. However, the significant advantage of MMP-7 + iBALF score in differentiating cirrhosis (F4) (AUC = 0.844 vs. FIB-4 AUC = 0.767 alone) suggests that a stratified diagnostic strategy is needed for specific stages (e.g., advanced fibrosis). This finding highlights the potential of MMP-7 as a biomarker of liver fibrosis and may provide a new direction for the clinical management of children with BA. In this study, it was observed that serum MMP-7 levels were significantly positively correlated with surgical age (r = 0.408, P = 0.002), and in multivariate analysis, MMP-7 maintained an independent predictive value after adjusting for confounders, and MMP-7 was still significantly positively correlated with surgical age (r = 0.338, P = 0.013). This is similar to the findings of Yang et al. [30] and Sakaguchi et al. [31], which showed that patients had a positive correlation with age in terms of MMP-7 levels. These results suggest that MMP-7 may not only be a biomarker of liver fibrosis, but also closely related to the progression of the disease course in children with BA. When considering serum MMP-7 as a biomarker for liver fibrosis, potential influences from extrahepatic sources must be taken into account. Although this study confirmed correlations between MMP-7 levels and both fibrosis stage and surgical age—suggesting its relevance in reflecting disease progression—it is important to note that MMP-7 is also expressed in extrahepatic conditions such as congenital heart disease, malignant tumors, and other systemic inflammatory disorders [32]. Despite applying strict exclusion criteria to rule out obvious comorbidities, it remains challenging to completely eliminate interference from potential occult extrahepatic conditions on MMP-7 levels. Therefore, in clinical practice, particularly for BA patients with additional complications, the possibility of extrahepatic sources should be considered when interpreting MMP-7 results.In the future, it is necessary to verify the test with a larger sample and explore the cut-off value optimization strategy based on age stratification. This study showed that MMP-7 combined with iBALF score (AUC = 0.844) had good differential efficacy in liver cirrhosis (F4), but its diagnostic accuracy was still lower than that of intraoperative liver biopsy (gold standard). In clinical practice, the MMP-7 + iBALF score can be used as an alternative in primary care hospitals for the screening of children with suspected advanced fibrosis (≥ F3) when liver biopsy is not feasible, and can also be used to regularly detect changes in MMP-7 levels after surgery to assist in judging the progression of fibrosis. However, liver biopsy is still required as the final basis for diagnosis, especially in the early identification of fibrosis (F1-F2). This study had the following limitations: Firstly, the sample size included in this study was small and the stage distribution was uneven (only 8 cases in F1 stage), and the impact of confounding factors such as bile acid levels and postoperative complications was not systematically analyzed, which may reduce the statistical power. Secondly, 14 patients (including 2 perioperative deaths) were excluded, and the potential loss of advanced fibrotic features may affect the marker association analysis. In addition, this study is a two-center study and lacks external validation, and a multicenter study is needed to confirm the universality of MMP-7 combined with iBALF score. Finally, this study focused on the diagnostic value of MMP-7 in staging liver fibrosis and did not explore its prognostic relationship with NLS. While establishing such an association could enhance the clinical appeal of MMP-7 as a prognostic biomarker, the present findings—demonstrating the relatively high efficacy of MMP-7 combined with the iBALF score in identifying cirrhosis—retain significant clinical relevance for postoperative management, monitoring of portal hypertension, and liver transplantation assessment. In future work, we aim to expand the sample size, incorporate multidimensional covariates, and conduct prospective follow-up to systematically evaluate the comprehensive potential of MMP-7 in prognostic prediction and noninvasive diagnostic modeling. Conclusion The combination of MMP-7 and iBALF score offers reliable non-invasive support for assessing liver fibrosis stages in children with BA. The FIB-4 demonstrates high efficacy in identifying significant and advanced fibrosis, while the MMP-7 and iBALF score pairing achieves optimal diagnostic accuracy for cirrhosis. These non-invasive approaches are critical for clinical stratification in resource-limited settings. Further validation through multi-center studies and integration with imaging modalities could enhance their utility in a comprehensive diagnostic framework. Acknowledgements Not applicable. Clinical trial number Not applicable. Abbreviations Biliary atresia Kasai portoenterostomy Native liver survival Matrix Metallopeptidase 7 Aspartate aminotransferase-to-platelet ratio index Fibrosis 4 Score Infant biliary atresia liver fibrosis Receiver operating characteristic Area under the curve Authors’ contributions BL L conceived, designed and wrote the study. YY J and YF W completed data collection and did the statistical analysis. ZB Z and HX R supervised the data collection and provided financial support. HX R interpreted the data and modified the article. All authors read and approved the final manuscript. Funding This research was funded by the Establishment of a special cohort for digestive tract malformations within the comprehensive prevention and control verification system for birth defects in children (JX122C2022011); Shanxi Provincial Health Commission Project (2022074); Shanxi Provincial Children’s Hospital Hospital-level Project (2023002) and National Key Clinical Specialty Construction Project (Neonatology). Data availability All data generated or analyzed during this study are available from the corresponding authors upon reasonable request. Declarations Ethics approval and consent to participate The study was approved by the Ethics Committee of Shanxi Children’s Hospital (registered number: IRB-WZ-2024-031). Consent for publication Not applicable. Competing interests The authors declare no competing interests. Footnotes Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Data Availability Statement All data generated or analyzed during this study are available from the corresponding authors upon reasonable request.